Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries

    • Most Recent Events

    • 23 May 2020 Results (n=2503) assessing relationships between differences in fremanezumab exposure resulting from monthly and quarterly dosing schedules and efficacy endpoints of the phase 2 and 3 clinical trials for fremanezumab by developing E-R models, published in the Headache.
    • 17 Aug 2018 Results published in the Neurology
    • 10 Sep 2017 Results of post hoc analysis determining the percentage of patients with at least a 50% and 75% reduction in the number of days requiring acute medication use at month 1 that continued to sustain this 50% or 75% reduction over 3 months presented at the 2017 International Headache Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top